Holen Sie sich die Stockscreener-App
6.54
2.03%
0.13
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen - MarketBeat
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action - lincolnjournal.com
Aardvark Therapeutics Company Profile & Introduction - Moomoo
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges - TipRanks
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Morgan Stanley Maintains Aardvark Therapeutics(AARD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Why is Aardvark Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why is Aardvark Therapeutics stock surging today? - Investing.com
Aardvark Therapeutics Q2 EPS of $(0.66) beats $(0.91) estimate - scanx.trade
Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash - Stock Titan
Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Aardvark Therapeut reports Q2 2026 results — $73.9M cash; net loss $14.4M - TradingView
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary - TradingView
Aardvark Reports $14.4 Million Q2 Net Loss as ARD-101 Hold Continues - Quiver Quantitative
AARD: Q2 2026 net loss was $14.4M; cash reserves support operations into late 2027 - TradingView
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction - TradingView
Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions - Quiver Quantitative
Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026 - Stock Titan
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a shareEarnings Preview - TradingView
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
Aardvark Therapeutics (AARD) Surges 5.8% as Biotech Names Draw Fresh AttentionHead and Shoulders - dars.gov.et
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% LowerHagens Berman - PR Newswire
Aardvark Therapeutics Inc (AARD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aardvark Therapeutics Inc (AARD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aardvark Therapeutics Inc (AARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aardvark Therapeutics Inc (AARD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AARD|Aardvark Therapeutics Inc|Price:6.437|Chg%:+0.117 - TradingKey
TradingKey - TradingKey
Aardvark Therapeutics Inc (AARD) Balance Sheet - TradingKey
Aardvark Therapeutics Inc (AARD) Income Statement - tradingkey.com
Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AARD|Aardvark Therapeutics Inc|Price:6.680|Chg%:+0.360 - TradingKey
US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead - Streetwise Reports
Aardvark Therapeutics, Inc. Revenue Breakdown – NASDAQ:AARD - TradingView
Aardvark Therapeutics (AARD) Slips 1.25% as Stock Tests Key Support LevelsKAMA Signal - dars.gov.et
What is HC Wainwright's Forecast for AARD FY2027 Earnings? - MarketBeat
AARD Reiterates by HC Wainwright & Co. -- Price Target Announced at $6.00 - GuruFocus
H.C. Wainwright Maintains Aardvark Therapeutics(AARD.US) With Hold Rating, Announces Target Price $6 - Moomoo
Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds - TipRanks
Aardvark Therapeutics (AARD) Revenue BreakdownMain Composition - Moomoo
Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News - Moomoo
Morgan Stanley downgrades Aardvark Therapeutics (AARD) - MSN
What's going on with Aardvark Therapeutics stock on Wednesday? - MSN
[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Aardvark Therapeutics, Inc. SEC Filing (Jul 10, 2026) - Stock Titan
Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary - Quartr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - AOL.com
AARD Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageAnalyst Drop Coverage - dars.gov.et
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates DevelopmentNet Profit Margin - dars.gov.et
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index - marketscreener.com
Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options - Stock Titan
Aardvark Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index - marketscreener.com
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):